RNA logo

Avidity Biosciences, Inc. (RNA) Cash From Financing

Annual CFF:

$1.19B+$1.10B(+1170.30%)
December 31, 2024

Summary

  • As of today, RNA annual cash from financing is $1.19 billion, with the most recent change of +$1.10 billion (+1170.30%) on December 31, 2024.
  • During the last 3 years, RNA annual cash from financing has risen by +$1.02 billion (+576.26%).
  • RNA annual cash from financing is now at all-time high.

Performance

1-Year Change

+1170.3%

3-Year Change

+576.26%

5-Year Change

+1236.23%

15-Year Change

+23079.57%

RNA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

99.09%
RNA annual cash from financing is higher than 99.09% of companies in Healthcare sector

Range

All-Time High

$1.19B
RNA annual cash from financing is currently at an all-time high

3-Year Low

$93.86M
RNA annual cash from financing is currently +1170.30% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
RNA previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

Mar 2, 2026
RNA next annual earnings announcement is scheduled for Mar 2, 2026

OtherRNAcash flow metrics

Annual CFI

-$854.20M
RNA annual cash from investing is -$854.20 million

Annual CFO

-$300.87M
RNA annual cash from operations is -$300.87 million

Annual FCF

-$307.94M
RNA annual free cash flow is -$307.94 million

Annual CAPEX

$7.07M
RNA annual capital expenditures is $7.07 million

Quarterly CFF:

$850.37M+$846.59M(+22438.19%)
September 30, 2025

Summary

  • As of today, RNA quarterly cash from financing is $850.37 million, with the most recent change of +$846.59 million (+22438.19%) on September 30, 2025.
  • Over the past year, RNA quarterly cash from financing has increased by +$507.90 million (+148.31%).
  • RNA quarterly cash from financing is now at all-time high.

Performance

3-Month Change

+22438.19%

1-Year Change

+148.31%

3-Year Change

+2046.3%

5-Year Change

+63277.27%

RNA Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

99.73%
RNA quarterly cash from financing is higher than 99.73% of companies in Healthcare sector

Range

All-Time High

$850.37M
RNA quarterly cash from financing is currently at an all-time high

3-Year Low

$40.00K
RNA quarterly cash from financing is currently >+9900.00% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
RNA previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 2, 2026
RNA next earnings announcement is scheduled for Mar 2, 2026

OtherRNAcash flow metrics

Quarterly CFI

-$587.93M
RNA quarterly cash from investing is -$587.93 million

Quarterly CFO

-$156.17M
RNA quarterly cash from operations is -$156.17 million

Quarterly FCF

-$156.88M
RNA quarterly free cash flow is -$156.88 million

Quarterly CAPEX

$712.00K
RNA quarterly capital expenditures is $712.00 thousand

TTM CFF:

$869.80M+$507.90M(+140.34%)
September 30, 2025

Summary

  • As of today, RNA TTM cash from financing is $869.80 million, with the most recent change of +$507.90 million (+140.34%) on September 30, 2025.
  • Over the past year, RNA TTM cash from financing has dropped by -$340.72 million (-28.15%).
  • RNA TTM cash from financing is now -28.15% below its all-time high of $1.21 billion, reached on September 30, 2024.

Performance

3-Month Change

+140.34%

1-Year Change

-28.15%

3-Year Change

+606.25%

5-Year Change

+220.27%

RNA TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

99.29%
RNA TTM cash from financing is higher than 99.29% of companies in Healthcare sector

Range

All-Time High

$1.21B
RNA TTM cash from financing is currently -28.15% below its historical high of $1.21 billion

3-Year Low

$93.86M
RNA TTM cash from financing is currently +826.66% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
RNA previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 2, 2026
RNA next earnings announcement is scheduled for Mar 2, 2026

OtherRNAcash flow metrics

TTM CFI

-$309.43M
RNA TTM cash from investing is -$309.43 million

TTM CFO

-$580.54M
RNA TTM cash from operations is -$580.54 million

TTM FCF

-$592.26M
RNA TTM free cash flow is -$592.26 million

TTM CAPEX

$11.72M
RNA TTM capital expenditures is $11.72 million

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

RNA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+1170.3%+148.3%-28.1%
3Y3 Years+576.3%+2046.3%+606.3%
5Y5 Years+1236.2%+10000.0%+220.3%

RNA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+1170.3%at high>+9999.0%-28.1%+826.7%
5Y5-Yearat high+1236.2%at high>+9999.0%-28.1%>+9999.0%
All-TimeAll-Timeat high>+9999.0%at high>+9999.0%-28.1%>+9999.0%

RNA Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$850.37M(>+9900.0%)
$869.80M(+140.3%)
Jun 2025
-
$3.77M(+94.8%)
$361.90M(-55.0%)
Mar 2025
-
$1.94M(-85.9%)
$804.85M(-32.5%)
Dec 2024
$1.19B(+1170.3%)
$13.72M(-96.0%)
$1.19B(-1.5%)
Sep 2024
-
$342.46M(-23.3%)
$1.21B(+39.4%)
Jun 2024
-
$446.72M(+14.7%)
$868.10M(+88.6%)
Mar 2024
-
$389.44M(+1121.2%)
$460.35M(+390.4%)
Dec 2023
$93.86M(-72.9%)
$31.89M(>+9900.0%)
$93.86M(-69.3%)
Sep 2023
-
$40.00K(-99.9%)
$305.63M(-11.5%)
Jun 2023
-
$38.97M(+69.7%)
$345.21M(+0.1%)
Mar 2023
-
$22.96M(-90.6%)
$345.02M(-0.3%)
Dec 2022
$346.17M
$243.65M(+515.0%)
$346.17M(+181.1%)
Sep 2022
-
$39.62M(+2.2%)
$123.16M(-48.4%)
Jun 2022
-
$38.78M(+60.8%)
$238.77M(+19.1%)
DateAnnualQuarterlyTTM
Mar 2022
-
$24.11M(+16.8%)
$200.41M(+13.7%)
Dec 2021
$176.32M(-35.2%)
$20.64M(-86.7%)
$176.32M(+12.9%)
Sep 2021
-
$155.24M(>+9900.0%)
$156.13M(>+9900.0%)
Jun 2021
-
$423.00K(+2388.2%)
-$456.00K(-100.2%)
Mar 2021
-
$17.00K(-96.2%)
$270.54M(-0.6%)
Dec 2020
$272.04M(+204.9%)
$450.00K(+133.4%)
$272.04M(+0.2%)
Sep 2020
-
-$1.35M(-100.5%)
$271.59M(-0.2%)
Jun 2020
-
$271.42M(>+9900.0%)
$272.22M(+1702.4%)
Mar 2020
-
$1.52M(+312.9%)
$15.10M(-13.2%)
Dec 2019
$89.23M(+1634.7%)
-
-
Sep 2019
-
-$712.00K(-105.0%)
$17.41M(-3.9%)
Jun 2019
-
$14.30M(+274.1%)
$18.12M(+374.1%)
Mar 2019
-
$3.82M
$3.82M
Dec 2018
$5.14M
-
-

FAQ

  • What is Avidity Biosciences, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Avidity Biosciences, Inc.?
  • What is Avidity Biosciences, Inc. annual cash from financing year-on-year change?
  • What is Avidity Biosciences, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Avidity Biosciences, Inc.?
  • What is Avidity Biosciences, Inc. quarterly cash from financing year-on-year change?
  • What is Avidity Biosciences, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Avidity Biosciences, Inc.?
  • What is Avidity Biosciences, Inc. TTM cash from financing year-on-year change?

What is Avidity Biosciences, Inc. annual cash from financing?

The current annual cash from financing of RNA is $1.19B

What is the all-time high annual cash from financing for Avidity Biosciences, Inc.?

Avidity Biosciences, Inc. all-time high annual cash from financing is $1.19B

What is Avidity Biosciences, Inc. annual cash from financing year-on-year change?

Over the past year, RNA annual cash from financing has changed by +$1.10B (+1170.30%)

What is Avidity Biosciences, Inc. quarterly cash from financing?

The current quarterly cash from financing of RNA is $850.37M

What is the all-time high quarterly cash from financing for Avidity Biosciences, Inc.?

Avidity Biosciences, Inc. all-time high quarterly cash from financing is $850.37M

What is Avidity Biosciences, Inc. quarterly cash from financing year-on-year change?

Over the past year, RNA quarterly cash from financing has changed by +$507.90M (+148.31%)

What is Avidity Biosciences, Inc. TTM cash from financing?

The current TTM cash from financing of RNA is $869.80M

What is the all-time high TTM cash from financing for Avidity Biosciences, Inc.?

Avidity Biosciences, Inc. all-time high TTM cash from financing is $1.21B

What is Avidity Biosciences, Inc. TTM cash from financing year-on-year change?

Over the past year, RNA TTM cash from financing has changed by -$340.72M (-28.15%)
On this page